163 related articles for article (PubMed ID: 24468268)
21. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
23. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
25. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
26. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
Olvedy M; Tisserand JC; Luciani F; Boeckx B; Wouters J; Lopez S; Rambow F; Aibar S; Thienpont B; Barra J; Köhler C; Radaelli E; Tartare-Deckert S; Aerts S; Dubreuil P; van den Oord JJ; Lambrechts D; De Sepulveda P; Marine JC
J Clin Invest; 2017 Jun; 127(6):2310-2325. PubMed ID: 28463229
[TBL] [Abstract][Full Text] [Related]
27. Genetic alterations in signaling pathways in melanoma.
Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
[TBL] [Abstract][Full Text] [Related]
28. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.
Schramm SJ; Li SS; Jayaswal V; Fung DC; Campain AE; Pang CN; Scolyer RA; Yang YH; Mann GJ; Wilkins MR
Pigment Cell Melanoma Res; 2013 Sep; 26(5):708-22. PubMed ID: 23738911
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
31. Genes involved in melanoma: an overview of INK4a and other loci.
Castellano M; Parmiani G
Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
[TBL] [Abstract][Full Text] [Related]
32. Genetic progression of metastatic melanoma.
Rodolfo M; Daniotti M; Vallacchi V
Cancer Lett; 2004 Oct; 214(2):133-47. PubMed ID: 15363539
[TBL] [Abstract][Full Text] [Related]
33. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
34. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
[TBL] [Abstract][Full Text] [Related]
35. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
[TBL] [Abstract][Full Text] [Related]
36. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
Kunz M; Hölzel M
Cancer Metastasis Rev; 2017 Mar; 36(1):53-75. PubMed ID: 28210865
[TBL] [Abstract][Full Text] [Related]
37. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
38. In this issue--oncogenes, tumor suppressor genes and melanocytic lesions.
Udey MC; Hornyak TJ
J Invest Dermatol; 2004 May; 122(5):VII-VIII. PubMed ID: 15140248
[No Abstract] [Full Text] [Related]
39. NUAK2: an emerging acral melanoma oncogene.
Namiki T; Coelho SG; Hearing VJ
Oncotarget; 2011 Sep; 2(9):695-704. PubMed ID: 21911917
[TBL] [Abstract][Full Text] [Related]
40. Oncogenes in melanomas.
Albino AP; Shea CR; McNutt NS
J Dermatol; 1992 Nov; 19(11):853-67. PubMed ID: 1293174
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
